MiMedx estimates and price target raised at Canaccord Canaccord raised its estimates and price target on MiMedx following news that management has formally responded to the FDA and proposed moving forward with clinical trials required to support an IND and BLA for its micronized products. The firm raised its price target to $8 to reflect continued sales of micronized products and reimbursement changes which could provide additional upside to estimates. Shares are Buy rated.
News For MDXG From The Last 14 Days
Check below for free stories on MDXG the last two weeks.
MiMedx was downgraded on January 6 at Northland Securities Shares of MiMedx are moving lower on incorrect reports that Northland Securities downgraded shares today. The firm downgraded shares on January 6 to Market Perform and maintains its rating.